Weil Company Inc. lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 17.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 14,600 shares of the life sciences company’s stock after selling 3,103 shares during the quarter. Weil Company Inc.’s holdings in Illumina were worth $3,996,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of the stock. First Citizens Bank & Trust Co. bought a new stake in Illumina in the third quarter worth $961,000. Signal Advisors Wealth LLC purchased a new position in Illumina during the third quarter worth $325,000. B. Riley Wealth Advisors Inc. purchased a new position in Illumina during the third quarter worth $425,000. McCollum Christoferson Group LLC bought a new position in Illumina during the third quarter valued at $285,000. Finally, NorthCrest Asset Manangement LLC increased its position in Illumina by 2.7% during the third quarter. NorthCrest Asset Manangement LLC now owns 8,357 shares of the life sciences company’s stock valued at $2,211,000 after acquiring an additional 220 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.
Analysts Set New Price Targets
Several brokerages have recently weighed in on ILMN. Evercore reissued an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. TD Cowen lifted their price target on shares of Illumina from $210.00 to $270.00 and gave the stock a “hold” rating in a research note on Tuesday. Argus lifted their price target on shares of Illumina from $180.00 to $235.00 and gave the stock a “buy” rating in a research note on Thursday, September 3rd. Stifel Nicolaus upped their price target on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a report on Friday, July 31st. Finally, Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Sunday. Ten investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Illumina presently has a consensus rating of “Hold” and an average target price of $225.94.
Illumina News Summary
Here are the key news stories impacting Illumina this week:
- Positive Sentiment: BioInsight Platform strengthens Illumina’s AI and software narrative. The company launched a unified environment combining genomic and multiomic analysis tools, purpose-built AI, curated biological data, and an updated DRAGEN secondary-analysis offering. The platform could make Illumina’s tools easier to use, support recurring software revenue, and help researchers move faster from sequencing data to actionable insights. Illumina BioInsight Platform announcement
- Positive Sentiment: SpliceAI2 may broaden the clinical-genomics opportunity. Coverage of Illumina’s new genomic model suggests that advances in AI-driven variant interpretation could improve the company’s positioning in clinical testing and precision medicine, though commercial adoption and regulatory validation remain key uncertainties. SpliceAI2 coverage
- Neutral Sentiment: Illumina established a $1 billion commercial-paper program and a new dealer agreement. The arrangements should improve short-term financing flexibility, but they also provide access to additional borrowing and are not, by themselves, evidence of higher operating performance. Commercial paper program announcement
- Neutral Sentiment: Upcoming third-quarter results are expected to show only low-single-digit earnings growth. The earnings preview gives investors a near-term catalyst, but expectations appear modest compared with the stock’s substantial recent rally. Illumina earnings preview
- Negative Sentiment: Valuation has become a significant concern. Analysts note that ILMN’s large share-price gain may already reflect much of the expected sequencing recovery and AI upside, leaving less room for disappointment if growth or cash-flow improvement slows. Illumina valuation analysis
- Negative Sentiment: A voluntary global recall affects certain diagnostic sequencers because of a DRAGEN server security vulnerability. The issue reportedly involves server configuration rather than sequencing accuracy or core hardware, and 80 units are affected. Even so, remediation costs, customer disruption, and cybersecurity concerns could weigh on sentiment. Illumina diagnostic sequencer recall
Insiders Place Their Bets
In related news, SVP Christensen Wedel sold 1,033 shares of Illumina stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the sale, the senior vice president owned 14,023 shares in the company, valued at $2,685,684.96. This trade represents a 6.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 119,501 shares of Illumina stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the sale, the director owned 770,350 shares of the company’s stock, valued at $168,244,440. The trade was a 13.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 2,061,850 shares of company stock valued at $436,479,102 over the last three months. Insiders own 2.90% of the company’s stock.
Illumina Price Performance
ILMN opened at $271.76 on Thursday. The business has a fifty day moving average of $231.55 and a 200 day moving average of $184.42. Illumina, Inc. has a 52-week low of $90.10 and a 52-week high of $309.35. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The stock has a market cap of $41.04 billion, a P/E ratio of 50.70, a PEG ratio of 3.84 and a beta of 1.41.
Illumina (NASDAQ:ILMN – Get Free Report) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter last year, the firm posted $1.19 earnings per share. The business’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.
Illumina Company Profile
Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.
The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.
Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.
Featured Stories
- Five stocks we like better than Illumina
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
